Company intelligence / Profile preview

Esperas Pharma Inc.

Montréal, Quebec, Canadadnb.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Esperas Pharma has completed dose-escalation studies of its lead compound ESP‑001 as monotherapy and in combination with gemcitabine. Proof-of-concept trials have been conducted in high-grade serous ovarian cancer and pancreatic cancer. An additional study combining ESP‑001 with low-dose gemcitabine for Ewing sarcoma patients is ongoing.

The company’s approach centers on developing the first oral CHK1 inhibitor, originally discovered by Eli Lilly, to address unmet needs in oncology.

Therapeutic areas: Oncology
Modalities: Small molecules (oral Check 1 inhibitor)
Industry: Biotech

Drug pipeline

1 asset

LY2880070

Partnerships

TVM Capital Life Science Innovation I L.P./SCSpFonds de solidarité FTQEli Lilly & Company (original discoverer of compound)

Beyond the preview

Go deeper on Esperas Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Esperas Pharma Inc..

Explore the full profile